Search clinical trials for: Tamoxifen

Total 471 results

Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7)

Advanced Metastatic Breast Cancer

Canada, Italy, Hungary, Taiwan, Turkey, Belgium, Germany, Spain, United States, Singapore, Australia, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, France, Russian Federation, Argentina, Brazil, Malaysia, Portugal, Col... and more
European Organisation for Research and Treatment...

Completed

Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer (LAPATAM)

Breast Cancer

France
National Cancer Institute (NCI)

Active, not recruiting

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7

United States
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

Mammographically Dense Breast

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast... and other conditions

United States
MedSIR

Active, not recruiting

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain)

Breast Cancer

Spain, Italy, France, United Kingdom, Germany, Portugal, Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

HIV Infections

United States, Puerto Rico
National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore

Active, not recruiting

Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376

Breast Cancer

Singapore
Shayna Showalter, MD

Active, not recruiting

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (POWER)

Breast Cancer Female

United States
GOG Foundation
Novartis Pharmaceuticals

Active, not recruiting

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Advanced, Persistent, or Recurrent Endometrial Cancer

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (TEXT)

Breast Cancer

United States, Australia, Switzerland, Italy, Canada, Belgium, Peru, United Kingdom, Egypt, New Zealand, Slovenia, South Africa, Sweden, Hungary, India, Germany, Brazil
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
Canadian Cancer Trials Group
Pfizer

Completed

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Breast Cancer

Canada
University of Alabama at Birmingham
M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Colorado... and other collaborators

Active, not recruiting

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam)

Breast Cancer

United States, Canada
Emory University
National Cancer Institute (NCI); Pfizer; National Institutes of Health (NIH)

Completed

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE)

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Metastatic Breast Carcinoma

United States
Oana Danciu, MD
Pfizer; Big Ten Cancer Research Consortium

Active, not recruiting

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Metastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Depression | Breast Cancer | Hot Flashes | Psychosocial Effects of Cancer and Its Treatment

United States
Balgrist University Hospital

Completed

Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy

Pain, Postoperative | Opioid Use | Nausea, Postoperative

Switzerland
ARCAGY/ GINECO GROUP
Novartis

Completed

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Breast Neoplasms | mTor Protein

France
ARCAGY/ GINECO GROUP
Bayer

Completed

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression (REGOVAR)

Ovarian Carcinoma

France
University of Nebraska
National Cancer Institute (NCI)

Completed

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

Breast Cancer

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8

United States
Yale University
Massachusetts General Hospital; Stony Brook University; Women and Infants Hospital...

Completed

Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer

Menopause

United States
Institut Cancerologie de l'Ouest

Active, not recruiting

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE)

Breast Cancer

France
Vanderbilt University Medical Center

Completed

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension (T3PAH)

Lung Diseases | Hypertension | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Primary Pulmonary Hypertension | Estrogens | Tamoxifen | Estrogen Receptor Antagonist | Hormone Antagonists

United States
Medical College of Wisconsin

Active, not recruiting

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Breast Cancer | Invasive Breast Cancer

United States
Daré Bioscience, Inc.

Completed

Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA (DARE-VVA1)

Vulvar Atrophy

Australia
Andrea DeCensi
European Institute of Oncology; Associazione Italiana per la Ricerca sul Cancro

Active, not recruiting

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up (TAM-01)

Breast Neoplasms | Carcinoma, Intraductal, Noninfiltrating | Recurrence, Local Neoplasm | Atypical Hyperplasia

Italy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Breast Cancer | Stage IV Breast Cancer

United States, Canada, Peru
Austrian Breast & Colorectal Cancer Study Group
AstraZeneca

Completed

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Early-stage Breast Cancer
European Institute of Oncology

Active, not recruiting

Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users (HOT)

Breast Cancer

Italy
Sanofi
European Organisation for Research and Treatment of Cancer - EORTC; Alliance... and other collaborators

Terminated

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (AMEERA-6)

Breast Cancer

Chile, China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Breast Cancer | Hot Flashes | Menopausal Symptoms

United States
British Columbia Cancer Agency
Canadian Cancer Society (CCS); NanoString Technologies, Inc.

Active, not recruiting

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (LALEAST)

Breast Cancer Female | Hormone Receptor Positive Tumor

Canada
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Completed

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Japan, Hong Kong, Singapore
Northwestern University
University of Illinois at Chicago

Completed

Stellate Ganglion Block (SGB) For Women for Breast Cancer

Hot Flashes | Hot Flushes

United States
CHU de Quebec-Universite Laval
GlaxoSmithKline

Completed

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Lower Urinary Tract Symptoms | Erectile Dysfunction | Prostate Cancer

Canada
Jennifer Lee Caswell-Jin
National Cancer Institute (NCI); QED Therapeutics, Inc.

Terminated

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 (TEXT-Bone)

Breast Cancer | Osteoporosis

Belgium, Australia, Switzerland
University of California, San Francisco
Amgen

Active, not recruiting

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
National Cancer Institute, Naples
University of Campania "Luigi Vanvitelli"

Active, not recruiting

HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. (HOBOE)

Breast Cancer

Italy
Maastricht University Medical Center

Completed

Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer (DATA)

Breast Cancer

Netherlands
Novartis Pharmaceuticals

Completed

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Canada
Queen Mary University of London

Active, not recruiting

Tamoxifen for the Prevention of Breast Cancer in High-Risk Women (IBIS-1)

Breast Cancer

United Kingdom
University Hospital, Basel, Switzerland

Completed

Tamoxifen in Duchenne Muscular Dystrophy (TAMDMD)

Duchenne Muscular Dystrophy

France, Spain, Germany, Netherlands, Switzerland, United Kingdom
European Organisation for Research and Treatment...
Sanofi; Novartis; Roche Pharma AG; Breast International Group; Agendia

Completed

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (MINDACT)

Breast Cancer

Netherlands

Search clinical trials for: Tamoxifen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations